Sientra collapse doomed execs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Semtech third quarter earnings per share miss estimate
Semtech, a Camarillo-based maker of semiconductors for cell phones and electronic devices, missed analyst estimates slightly when the company reported third quarter results Nov. 18. Semtech reported earnings per share of 16 cents. Analysts had expected earnings per share of 24 cents. Semtech slightly exceeded analyst revenue estimates of $115.4 million by posting earnings of Read More →
Goleta-based Sientra’s third quarter revenues down
Sientra Inc. sales were down 6.9 percent in the third quarter of 2015 but the results were largely unaffected by recent pandemonium at the company. The Goleta-based company reported third quarter results on Nov. 16 for the quarter that ended on Sept. 30, just one week after European regulators pulled products made by Sientra’s Brazilian Read More →
Goleta breast implant maker Sientra shakes up C-Suite
The writing was on the wall at Sientra. On Nov. 12, the company’s top executives took the fall. The embattled Goleta-based breast implant manufacturer cleaned house Thursday afternoon. Sientra founder and CEO Hani Zeini stepped down as CEO and he will be replaced by industry veteran Jeffrey Nugent. Nicholas Simon also resigned as chairman Read More →
Inogen’s third quarter earnings beat Wall Street expectations
Inogen, a Goleta-based maker of direct-to-consumer respiratory products, beat analyst estimates for revenue when the company released third quarter earnings on Nov. 10. Revenues were up 38.7 percent from $29.4 million during the third quarter of last year to $40.8 million this year. Analysts had predicted revenues of $37 million. Inogen also reported adjusted Read More →
Port Hueneme’s Stellar Biotechnologies trading on Nasdaq
Port Hueneme-based Stellar Biotechnologies started trading on the Nasdaq stock exchange Nov. 5. Stellar makes a protein for immunotherapy treatments using a unique sea snail only found off the coastal shores of a small part of California. Shares opened at $8.74 on Nov. 5 and were trading on the Nasdaq at $9.40 as of 11:30 Read More →
Goleta’s Sientra reassures investors, surgeons
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
